Results 21 to 30 of about 117 (84)

The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits. [PDF]

PLoS Medicine, 2016
In a Perspective, Jacqueline Deeen discusses challenges in balancing the individual and population risks and benefits for CYD-TDV (Dengvaxia), the first available dengue vaccine.
Jacqueline Deen
doaj   +1 more source

A dengue vaccine whirlwind update

Therapeutic Advances in Infectious Disease, 2023
Dengue virus (DENV) is a mosquito-borne single-stranded RNA virus of the Flaviviridae family with four serotypes (DENV1, DENV2, DENV3, and DENV4) circulating many tropical and subtropical regions of the world.
Ruwandi Kariyawasam, Mark Lachman, Saniya Mansuri, Sumontra Chakrabarti, Andrea K. Boggild   +4 more
doaj   +1 more source

Effect of a Vaccination against the Dengue Fever Epidemic in an Age Structure Population: From the Perspective of the Local and Global Stability Analysis

Mathematics, 2022
The effect of vaccination on the dengue fever epidemic described by an age structured modified SIR (Susceptible-Infected-Retired) model is studied using standard stability analysis.
Anusit Chamnan, Puntani Pongsumpun, I-Ming Tang, Napasool Wongvanich   +3 more
doaj   +1 more source

Performance Evaluation of a Dengue IgG Rapid Diagnostic Test Designed to Determine Dengue Serostatus as Part of Prevaccination Screening

Microbiology Spectrum, 2022
The World Health Organization has recommended prevaccination screening for prior dengue infection as the preferred approach prior to vaccination with the dengue vaccine CYD-TDV.
Vasco Liberal, Remi Forrat, Cong Zhang, Charles Pan, Matthew Bonaparte, Wushan Yin, Lingyi Zheng, Valeria Viscardi, Yukun Wu, Yasemin Ataman-Önal, Stephen Savarino, Catherine Chen   +11 more
doaj   +1 more source

Long-term safety follow-up of children from a randomized—controlled phase II b proof—of—concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD—TDV) in Thailand

Asian Pacific Journal of Tropical Medicine, 2019
Objective: To investigate the long-term safety of a tetravalent dengue vaccine (CYD-TDV) in children in a phase Π b follow-up study in Thailand. Methods: In the phase Π b study, children aged 4-11 years were randomized (2:1) to receive three injections ...
Kriengsak Limkittikul, Weerawan Hattasingh, Danaya Chansinghakul, Arunee Sabchareon, Wut Dulyachai, Carina Frago, T Anh Wartel, Edith Langevin, Sophia Gailhardou, Alain Bouckenooghe   +9 more
doaj   +1 more source

Cost-effectiveness of dengue vaccination in Puerto Rico.

PLoS Neglected Tropical Diseases, 2021
An effective and widely used vaccine could reduce the burden of dengue virus (DENV) around the world. DENV is endemic in Puerto Rico, where the dengue vaccine CYD-TDV is currently under consideration as a control measure.
Guido España, Andrew J Leidner, Stephen H Waterman, T Alex Perkins   +3 more
doaj   +1 more source

A case-control study to determine the effectiveness of a tetravalent dengue vaccine in the state of Paraná, Brazil

The Lancet Regional Health. Americas, 2022
Summary: Background: The Brazilian state of Paraná conducted a mass vaccination campaign against dengue with the tetravalent attenuated vaccine CYD-TDV. The campaign targeted thirty endemic municipalities.
José Cássio de Moraes, Irina Nastassja Riediger, Fernanda Crosewski, Denise Oliveira Garrett, Francieli Fontoura Fantinato, Karina Braga Ribeiro, Expedito José de Albuquerque Luna   +6 more
doaj   +1 more source

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines

Frontiers in Immunology, 2022
Dengue is the most common arboviral disease caused by one of four distinct but closely related dengue viruses (DENV) and places significant economic and public health burdens in the endemic areas.
Jue Hou, Weijian Ye, Jianzhu Chen, Jianzhu Chen   +3 more
doaj   +1 more source

Eficacia y seguridad de la vacuna contra el dengue

Evidencia. Actualización en la Práctica Ambulatoria, 2021
El dengue es un problema creciente para la salud pública mundial. En Argentina, los casos se han ido incrementado en los últimos años. La vacuna Dengvaxia (CYD-TDV) fue aprobada por la Agencia Nacional de Medicamentos, Alimentos y Tecnología en 2017, y ...
Maria Florencia Herrera Bornes
doaj   +1 more source

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination

Human Vaccines & Immunotherapeutics, 2017
Two large pivotal phase III studies demonstrated the efficacy of the tetravalent dengue vaccine (CYD-TDV; Dengvaxia®, Sanofi Pasteur) against all dengue serotypes.
Claire Vigne, Martin Dupuy, Aline Richetin, Bruno Guy, Nicholas Jackson, Matthew Bonaparte, Branda Hu, Melanie Saville, Danaya Chansinghakul, Fernando Noriega, Eric Plennevaux   +10 more
doaj   +1 more source